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Summary The new proliferation marker, tissue polypeptide-specific antigen (TPS), representing the specific
epitope M3 of tissue polypeptide antigen, and three conventional biochemical markers, CEA, CA 19-9 and
CA-195, were analysed in 69 patients with advanced gastrointestinal tumours. The aim of our study was to
assess the clinical relevance of these markers and to determine whether their use in monitoring the course of
the disease can reduce the need for senral imaging procedures. At baseline, pathologically elevated TPS levels
occurred in 90% of patients. CEA was elevated in 73%, CA 19-9 in 59% and CA-195 in 68%. With a
detection rate of >90% in both advanced colorectal (n = 37) and pancreatic cancer (n = 20), and of 75% in
gastric cancer (n = 12), TPS was the most sensitive marker in all three tumour types included in this analysis.
Serial evaluations of TPS and other biochemical markers were available in 39 patients undergoing palliative
systemic chemotherapy. Treatment with a fluorouracil-based regimen resulted in a partial response in 5127
patients with colorectal cancer, whereas 2/12 patients with pancreatic cancer responded to therapy with a
high-dose epirubicin combination regimen. All other patients had disease stabilisation or suffered from
progressive disease. When compared with the results of serial CT scanning, the TPS correlated best with the
course of the disease, the positive predictive value being 75% for a partial response, 96% for stable disease
and partial response combined and 100% for progressive disease. The corresponding values for CEA were
50%, 81% and 62% and were similar to those for CA 19-9 and CA-195. In summary, TPS seems to represent
a sensitive, clinically relevant and specific marker of proliferative activity in gastrointestinal cancer. According
to our preliminary results in colorectal and pancreatic cancer, TPS may be considered as the primary means of
monitoring treatment, and imaging reduced to confirm the response.
Keywords: tissue polypeptide antigen (TPS); tumour markers; gastrointestinal cancer
Gastrointestinal (GI) tumours are the most common type of
potentially fatal malignancies in the world, and affect
approximately 10,000 patients a year in Austria (Friedl,
1990). Since there is no effective screening modality or
chemoprevention, most patients present in the advanced
stages when the tumour is beyond surgical cure. Conven-
tional chemotherapy has shown only modest activity in
advanced GI tumours. Although recent advances might have
improved the situation in colorectal cancer (Nordic Gastro-
intestinal Tumor Adjuvant Therapy Group, 1992; Scheit-
hauer et al., 1993), clinical trials with new drugs and
regimens are certainly warranted. An important issue in the
chemotherapeutic management of these patients with both
conventional treatment regimens and new drugs remains the
early identification of non-responders, who may be spared
further treatment with associated toxicity. It may also be
important in some cases to evaluate the maximal response,
which may allow treatment discontinuation. The response to
systemic chemotherapy is usually assessed by serial imaging,
commonly in the form of CT scanning. Evaluation by this
means is, however, expensive and time-consuming for the
patient. A simple and inexpensive method to monitor re-
sponse would be the repeated measurement of tumour mark-
ers such as carcinoembyronic antigen (CEA), CA 19-9 or
CA-195, which are commonly elevated in patients with gast-
rointestinal cancer (Martin et al., 1976; Safi et al., 1978;
Kornek et al., 1992; Ward et al., 1993). It is recognised,
however, that these markers do not always accurately reflect
the course of the disease. The limitations to their use in
isolation is the overestimation of the number of patients who
respond to treatment and, more seriously, underestimation of
the number suffering progressive disease as demonstrated on
CT (Allen-Mersh et al., 1986; Ward et al., 1993).
A potentially attractive alternative to conventional tumour
markers may be recently defined markers indicating tumour
proliferation (Bj6rklund and Bj6rklund, 1983; Bjorklund et
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al., 1987). Since dividing cells are generally more vulnerable
to cytotoxic chemicals or radiation than resting ones,
estimates of the tumours' proliferative activity may not only
help to reduce the need for serial imaging, but may also be
important with respect to the scheduling of anti-cancer
therapy. During the late S and G2-phases of the cell cycle a
substance termed tissue polypeptide antigen (TPA) is syn-
thesised and released immediately into the body fluids. The
concentration of the antigen in the serum seems to be a
relevant indicator of the proliferative activity of cancer cells
as assessed in previous clinical investigations (Gitsch et al.,
1992; Van Dalen, 1992). Extensive monoclonal mapping of
TPA revealed 35 epitopes, only two of which are essential for
the original TPA specificity as related to proliferative activity
and common human tumour antigenicity (Bj6rklund et al.,
1987). The corresponding monoclonal antibody, M3, was
introduced as tracer in a new in vitro immunoradiometric
assay for the quantitation of tissue polypeptide-specific
antigen (TPS) in serum and other body fluids.
The purpose of our study was to investigate the clinical
relevance of TPS in the management of patients with
advanced gastrointestinal tumours in comparison with CEA,
CA 19-9 and CA-195.
Patients and methods
Patients
Sixty-nine patients with histologically ascertained advanced
gastrointestinal carcinomas were studied; 43 were male and
26 female. The median age was 62 (range 37-75) years.
Thirty-seven patients had metastatic colorectal cancer, 20
patients had advanced pancreatic and 12 had advanced gast-
ric cancer. The patients were a consecutive series in chemo-
therapy studies conducted at the oncology clinics of the
University of Vienna, Austria, which required that the
disease was measurable on CT scan and/or radiography.
Patients with colorectal cancer were treated with a three-drug
combination regimen consisting of 5-fluorouracil (FU), leu-covorin (LV) and cisplatin plus supportive care or supportive
care alone (Scheithauer et al., 1993). Patients with advanced
pancreatic cancer participated in a phase IJII trial of epiru-
bicin, dexverapamil, a novel multidrug-resistance reverting
agent, plus granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) (Kornek et al., 1993a). Patients with advanced
gastric cancer received systemic chemotherapy with FU, LV
and epirubicin (Kornek et al., 1993b).
Measurement ofbiochemical markers
A 10 ml sample of venous blood was obtained from all
patients after overnight fasting at baseline, and also in 39
patients undergoing systemic chemotherapy at monthly inter-
vals thereafter for tumour and proliferation marker assess-
ments. The plasma was immediately separated, and frozen at
-20°C until assayed. All samples were coded and analysed
independently of clinical information about the subjects.
TPS was measured by a solid-phase, two-site immuno-
radiometric assay (TPS IRMA Kit, Beki Diagnostic, Bromma,
Sweden). All samples were run in duplicate. The mean co-
efficient of vanration between assays was 8%. Conventional
tumour markers CEA, CA 19-9, and CA-195 (all obtained
from Hybritech, Liege, Belgium) were measured by standard
(immunoradiometnrc) procedures. The normal range for TPS
was 0-80 U 1', CEA 0-5 ng ml-', CA 19-9 0-37 U 1-' and
CA-195 0-0 U ml-' as indicated by the manufacturers.
Clinically relevant changes in TPS and conventional
tumour marker levels were defined as a greater than 25%
increase or a greater than 50% decrease in the markers on at
least two occasions 1 month apart. For the purposes of the
study, such an increase was considered to be positive as
regards the detection of progressive disease (PD) and such a
decrease considered to be positive in the assessment of a
response (CR, PR) to treatment. A less than 25% increase
and less than 50% decrease in the markers on at least two
occasions 1 month apart was considered to indicate disease
stabilisation (SD).
Assessment of tumour response
In the 39 patients undergoing systemic chemotherapy and
longitudinal evaluation of biochemical marker levels, CT
scanning and radiography were performed in the 2 weeks
before treatment started. and at 2 monthly intervals there-
after to assess response to treatment. Objective tumour res-
ponse was graded in accordance with the World Health
Organization (WHO) standard criteria (Miller et al., 1981).
Changes in biochemical marker levels in relationship to CT
and/or radiography in patients achieving objective response
or disease stabilisation or suffering from progressive disease
were expressed in terms of sensitivity, specificity and positive
and negative predictive value.
Statistical analysis
Comparisons between unpaired groups were made using the
Mann-Whitney U-test and correlation assessed using the
Spearman rank order correlation (Cohen and Holliday,
1982).
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Resuhs
Sixty-nine patients with metastatic gastrointestinal malignan-
cies were evaluated during the period of the study. The
proliferation marker TPS plus the conventional biochemical
markers CEA. CA 19-9, and CA-195 were measured on at
least one sample in all subjects. A comparative analysis of
the serum levels at the time of diagnosis of advanced disease
is provided in Table I. At baseline, pathologically elevated
TPS levels occurred in 62 of these patients (89.9%). The
CEA was elevated in 50 (72.5%), CA 19-9 in 41 (59.4%) and
CA-195 in 47 (68.1%). With a detection rate of 92% in
patients with advanced colorectal cancer, 95% in pancreatic
cancer and 75% in gastric cancer, TPS was the most sensitive
marker in all three tumour types included in this analysis.
Considering only the patients in whom the markers were
elevated, the median level of TPS was 285 (82-9,900)
U ml-', of CEA 180 (5.3-6,000) ng ml-, of CA 19-9 5,430
(40-18,500) Uml-' and of CA-195 72 (13-21,300) Uml-'.
There was no correlation between the presence of an elevated
marker and the site of metastatic disease. In the subpopula-
tion of patients with abnormal pretreatment marker levels,
there was a fairly good correlation between TPS and CEA
(Spearman rho 0.831; P =0.0001), TPS and CA 19-9 (rho
0.528; P = 0.005), as well as TPS and CA-195 (rho 0.589;
P=0.00l).
Serial evaluations of TPS and other biochemical markers
were available in 39 patients undergoing palliative systemic
chemotherapy. Twenty-seven of these had advanced colorec-
Table H The sensitivity, specificity and positive and negative predic-
tive values of serial biochemical marker measurements in evaluating a
partial response as assessed by imaging procedures
TPS CEA CA 19-9 CA-195
Sensitivity(%) 6 7 3 5 1 3 2,'5
Specificity (0) 29 31 21 24 18 18 20/22
Positive predictive
value (%) 6 8 3 6 1 1 2,4
Negative predictive
value (%) 29 30 21 23 18 20 20 23
Values indicated are number of patients.
Table III The sensitivity, specificity and positive and negative predic-
tive values of serial biochemical marker measurements in evaluating
partial responseplusstablediseaseversusprogressive diseaseasassessed
by imaging procedures
TPS CEA CA 19-9 CA-195
As related to As related to
response+stable disease progressive disease
Sensitivity 24 24 13 18 9 13 12 18 Specificity
Specificity 13 14 8 11 7 8 811 Sensitivity
Positive Negative
predictive 24 25 13 16 9 10 12 15 predictive
value value
Negative Positive
predictive 13 13 8 13 7 11 8 14 predictive
value value
Values indicated are number of patients.
Table I Summary of TPS. CEA. CA 19-9. and CA-195 serum levels in patients with advanced gastrointestinal
malignancies
Biochemical marker levelsa
Number of TPS CEA CA 19-9 CA-195
Diagnosis patients >80 UV' >5ngml-' >37 LUT-' >10L 1-
Colorectal cancer 37 34 (91.9) 29 (78.4) 18 (48.6) 23 (62.2)
Pancreatic cancer 20 19 (95.0) 14 (70.0) 18 (90.0) 17 (85.0)
Gastric cancer 12 9 (75.0) 7 (58.3) 5 (41.6) 7 (58.3)
Total 69 62 (89.9) 50 (72.5) 41 (59.4) 47 (68.1)
TPS. tissue polypeptide-specific antigen; CEA, carcinoembryonic antigen. 'Values in parentheses represent the
percentage of patients with abnormal levels of the indicated biochemical marker.ipshw .ebin.I GIq U ~ inmr Om G Komeketa
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tal cancer and 12 had pancreatic cancer. Over the course of
the patients' treatment there were seven episodes in which the
diseasepartially responded to therapy, 18 episodes ofdisease
stabiisation and 14 episodes of progresve disease. Com-
parisons between the trend in the markers (where those
markers that were elevated at the start of the peiod being
considered) and the CT findings are shown in Tables II and
IH. A 50% fall in TPS was helpful in 6/7 patients in predict-
ing partial response on CT. The other biochemical markers
were kss sensitive (Table E), which becomes paricuarly
evident if all patients (i.e. also those with normal preteat-
ment values) were to be included in the analysis. Whereas the
sensitivity of TPS would remain uneffected (86%), the sensi-
tivity ofCEA, CA 19-9 and CA-195 would drop to values as
low as 43%, 14% and 29% rpectively. According to the
rather stringnt definition of a 50% fall in order to predict
PR, the specificity was accptable for all four markers with
an approximate value of 90% each. The postive predicve
value was 75% for a fall in TPS and 50% for a fall in the
other biochemical markers [disregarding 1/1 (100%) for CA
19-91. The negative predictive value for a partial reonse
ranged from 97% for TPS to 87% for CA-195.
When consideration was given to patients with both objec-
tive response and stable disa while on treatment, the
sensitivity of TPS improved to 100%, and the specificity was
unaffected (93%). Whereas an improvement was also noticed
for the sensitivity of the other biochemical markers (Table
HI), their specifiity was adversely iflu , with values
ranging from 73% to 88%. The reutant posiie ive
values were 96%, 81%, 90% and 80% for TPS, CEA, CA
19-9 and CA-195 respectively. The negative predictive vahle
was better for the proliferation marker TPS (100%) than for
the conventional tumour markers with an approximate value
of 60% each. The sensitivity, spificity and positive and
negtive predictive values of (at least 25%) rising markers in
terms of progressive disease, which are derivable from/
parallel the results of the former analysis, are also given in
Table lI.
Measurement of tumour-associated antigens by polyclonal
and monoclonal antibody techniques esents a promisng
development in clinical oncology. In several tumour types,
incuding ovarian, testicular, prostatic and hepatocellular car-
cinoma, mesurements of certain crculating antigens have
proven useful in diagnosis, evaluation oftherpeutic outcome
and follow-up. In patients with gastrointestinal cancer
tumour markers such as CEA, CA 19-9, CA-195 and others
are commonly eklvated. Evaluation of their use in the
management of these patients, however, has remained
controversial (Main, 1987; Moertel et al., 1993). According
to the relationship of the marker level with tumour burden,
their major applhtion lies in monitoring treatment response
m patients with advanced diease (Malkin, 1987). Still, there
remain several limitations to their use, such as absence of
elevated values in some patients, and probable heterogeneity
of production of the marker substances among the cells of
the tumour population. Accordingly, lonidinal evaluation
of srum klvs may result in incorrect estimation of the
number of patients who respond to treatment or, more
seriously, failure to detect patients suffering from progressive
disease as demonstrated by imaging procedures.
The monoclonal TPS assay, measuring the specific M3
epitope of tissue pobypeptide antigen, is advocated to
monitor cell multiplication in cancer patients (Bj6rklund and
Bj6rklund, 1983; Bjrklund et al., 1987). Seri measurements
of a tumour's proliferative activity by TPS may provide a
more sensitie and clinically relevant means to judge the
efficacy of treatment as compared with conventional tumour
markers that only reflect tumour burden. Recent studies have
suggestd, in fact, that this may be the case in several
different tumour types (Gitsch et al., 1992; van Dalen, 1992;
Marrink et al., 1993). The aim of the present investigation
was to assess the potential role of TPS and three conven-
tional gastrointestinal tumour markers in monitoring the
course of the diseas in patients undergoing palliative
systmic chemotherapy. Our data suggest that the new pro-
liferation marker TPS appears to be the most useful bio-
chemical marker in that it is elevated in more than 90% of
the patients with advanced diseas, and has the best predic-
ti value. Among the three conventional markers, CEA, the
most commonly usd tumour marker, was confirmed to yield
inically more rekvant information than CA 19-9 or CA-195
(Ward et al., 1993). Wben TPS was elevated, however, no
additional information was obtained from simultaneous
measurement of CEA (or one of the other tumour markers).
Preteatment TPS- and tumour marker values tended to
change in synchrony, as indicated by a fairly good correla-
tion between them.
It is clear that neither proliferation markers nor conven-
tional tumour markers can replace the use of imaging proce-
dures in the mnagement and assent of cancer patients.
According to our results in paients with advanced colorectal
and pancreatic cancer, however, TPS seems sufficintly sen-
sitive and useful to be employed as the primary means of
follow-up. In addition, TPS may be used with some
confidence in patients in whom the disease is not easily
evahlable, such as those with diffuse intraperitoneal metas-
tass.
In conclusion, we would recommend that serial TPS
measurements are performed on all patients undergoing
chemotherapy for advanced gastrointesiunal canr. Only m
the few cases where TPS proves not to be elevated should an
alternative biochemical marker such as CEA, CA-19/9 or
CA-195 be used. The marker can be used as the primary
means ofmonitoring treatment, and imaging used to confirm
the response.
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